248 related articles for article (PubMed ID: 15649254)
1. EPHA2/EFNA1 expression in human gastric cancer.
Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
[TBL] [Abstract][Full Text] [Related]
2. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
3. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
4. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.
Han L; Dong Z; Qiao Y; Kristensen GB; Holm R; Nesland JM; Suo Z
Gynecol Oncol; 2005 Nov; 99(2):278-86. PubMed ID: 16061279
[TBL] [Abstract][Full Text] [Related]
6. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma.
Xu F; Zhong W; Li J; Shanshen Z; Cui J; Nesland JM; Suo Z
Anticancer Res; 2005; 25(4):2943-50. PubMed ID: 16080548
[TBL] [Abstract][Full Text] [Related]
8. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
9. EphA2 expression is associated with aggressive features in ovarian carcinoma.
Thaker PH; Deavers M; Celestino J; Thornton A; Fletcher MS; Landen CN; Kinch MS; Kiener PA; Sood AK
Clin Cancer Res; 2004 Aug; 10(15):5145-50. PubMed ID: 15297418
[TBL] [Abstract][Full Text] [Related]
10. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B
Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.
Wu D; Suo Z; Kristensen GB; Li S; Troen G; Holm R; Nesland JM
Gynecol Oncol; 2004 Aug; 94(2):312-9. PubMed ID: 15297167
[TBL] [Abstract][Full Text] [Related]
12. [Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis].
Xu JS; Zhang JX; Geng TH; Wang YF; Wang XL; Zuo LF
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):438-41. PubMed ID: 19950554
[TBL] [Abstract][Full Text] [Related]
13. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer.
Kataoka H; Igarashi H; Kanamori M; Ihara M; Wang JD; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Maruyama K; Nakamura T; Arai H; Kajimura M; Hanai H; Tanaka M; Sugimura H
Cancer Sci; 2004 Feb; 95(2):136-41. PubMed ID: 14965363
[TBL] [Abstract][Full Text] [Related]
14. [Alteration of early growth response 1 expression in gastroenterological cancers and its biological significance].
An J; Guo RF; Zhang L; Geng PL; Lü YY
Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1384-9. PubMed ID: 18953875
[TBL] [Abstract][Full Text] [Related]
15. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.
Cui XD; Lee MJ; Yu GR; Kim IH; Yu HC; Song EY; Kim DG
Int J Cancer; 2010 Feb; 126(4):940-9. PubMed ID: 19642143
[TBL] [Abstract][Full Text] [Related]
16. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland.
Shao Z; Zhu F; Song K; Zhang H; Liu K; Shang Z
J Oral Maxillofac Surg; 2013 May; 71(5):869-78. PubMed ID: 23298804
[TBL] [Abstract][Full Text] [Related]
17. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
19. Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling.
Yang YH; Deng H; Li WM; Zhang QY; Hu XT; Xiao B; Zhu HH; Geng PL; Lu YY
Clin Cancer Res; 2008 Jan; 14(1):74-81. PubMed ID: 18172255
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]